Lilly's Abemaciclib On Par With Ibrance In Breast Cancer, But Not 'Clearly Superior'

Despite returning positive results in the MONARCH-3 trial, Lilly's breast cancer therapy abemaciclib has sparked mixed reactions at ESMO; the big pharma will need to work on differentiating the drug from other CDK 4/6 therapies.

Two wild goats play-fight on the edge of a rock cliff with horns interlocked. — Lilly's abemaciclib will face off with Pfizer's Ibrance if approved in 2018

It is unclear how much commercial traction Eli Lilly & Co. will get with incoming breast cancer therapy abemaciclib, analysts from Bernstein said after the big pharma presented Phase III data from the MONARCH-3 trial at the European Society for Medical Oncology's annual meeting in Madrid.

"The presentation of full MONARCH-3 results will largely support investors' disbelief that abemaciclib will be clearly superior [to market leading drugs], despite LLY continuing to put its best face forward,"...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Angelini Advances Brain Health Ambitions With GRIN Pact

27 May 2025

• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

Sweden’s Hansa Slims Down Ahead of Key Readouts

27 May 2025

• By Kevin Grogan

New CEO Renée Aguiar-Lucander is marking her mark.

Gilead Ready To Go After Hepatitis D Again

26 May 2025

• By Joseph Haas

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.

Progress In The Effort To Improve Outcomes In SCLC

26 May 2025

• By Jessica Merrill

Several drug makers are working to bring new advances to small-cell lung cancer, a fast-growing cancer with limited treatment options.

Pipeline Watch: 12 Approvals And 26 Phase III Readouts

26 May 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.